Employee Benefits News examines legal developments that impact the employee benefits and executive compensation employers provide, including federal and state legislation, rules from federal...
Allergan plc’s connection to an alleged price-fixing scheme among generic drug makers spawned a proposed class action Feb. 14, with an Allergan employee claiming he lost retirement savings by investing in the company’s stock ( Xie v. Inv. Comm. & Benefits Oversight Comm. of Allergan Inc. Sav. & Inv. Plan , C.D. Cal., No. 8:17-cv-00271, complaint filed 2/14/17 ).
The complaint accuses Allergan’s benefits plan committee and the company’s chief financial officer, Maria Teresa Hilado, of failing to protect workers from a 23 percent drop in Allergan’s stock price in connection with an ongoing Department of Justice investigation into price collusion among major pharmaceutical companies. Hilado and the committee breached their duties under federal benefits law by continuing to let workers invest retirement savings in Allergan stock, which carried an artificially inflated price tag before news of the investigation broke, the complaint alleges.
Allergan—which was subpoenaed in connection with the DOJ investigation in 2015—is the first drug company to be sued over related retirement plan losses. In December 2016, 20 state attorneys’ general filed antitrust charges against six drug companies, including Aurobindo, Heritage, Mylan and Teva, without naming Allergan. The DOJ filed its first criminal charges that same month, targeting twoformer Heritage executives.
Litigation over alleged drug price fixing continues to swirl, with twonew lawsuits targeting Allergan in the past month. The suits, filed by California’s attorney general and the Federal Trade Commission, challenge the pricing of lidocaine patches intended to treat shingles. Allergan has challenged the FTC lawsuit, which was filed Jan. 23 in a California federal court, as “flagrant forum shopping” and an attempt to circumvent a settlement entered in a Pennsylvania-based federal court.
Allergan also faces multiplesecuritieslawsuits over stock losses connected to the DOJ investigation. Those lawsuits claim that hundreds of thousands of Allergan shareholders were harmed by the alleged fraud. By contrast, the most recent lawsuit alleges violations of the Employee Retirement Income Security Act and seeks relief on behalf of “at least 19,000" individuals who held Allergan stock in the company’s retirement plan. It’s the first time Allergan has been sued under ERISA in at least five years, according to Bloomberg Law Litigation Analytics.
The ERISA lawsuit will likely face obstacles in the federal courts, which have been increasingly likely to dismiss ERISA claims involving employer stock losses since a seminal U.S. Supreme Court decision in 2014.
Since that decision, a number of companies have beaten these “stock-drop” lawsuits, with courts rejecting claims involving the company stock plans of Lehman Brothers, General Motors, RadioShack Corp., J.C. Penney, Whole Foods Corp., and Sanofi-Aventis U.S. LLC.
The ERISA lawsuit against Allergan was filed in the U.S. District Court for the Central District of California by Zamansky LLC.
Allergan didn’t immediately respond to inquiries about the new lawsuit.
To contact the reporter on this story: Jacklyn Wille in Washington at email@example.com
To contact the editor responsible for this story: Jo-el J. Meyer at firstname.lastname@example.org
Text of the complaint is at http://www.bloomberglaw.com/public/document/Xie_v_The_Investment_Committee_and_Benefits_Oversight_Committee_o.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)